How Bio-Techne's Spatial Biology COMET Expansion (TECH) Has Changed Its Investment Story

• In March 2026, Bio-Techne expanded its COMET spatial biology portfolio with new SPYRE Focus Panels, SPYRE Amplification Kits, and upgraded HORIZON image analysis software to enhance automated, modular tissue analysis workflows from assay design through interpretation.
• This expansion deepens Bio-Techne’s footprint in high-content spatial biology by combining validated, modular antibody panels with seqLA-based signal amplification to help researchers extract richer insights from scarce tissue samples.
• We’ll now explore how the COMET portfolio expansion, particularly the SPYRE Focus Panels, may influence Bio-Techne’s existing investment narrative.

Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.

Bio-Techne Investment Narrative Recap

To own Bio-Techne, you need to believe its specialized tools in spatial biology, cell therapy, and diagnostics can steadily deepen their role in research and clinical workflows. The COMET expansion broadens Bio-Techne’s spatial biology offering, but it does not materially change the near term picture where funding pressures at biotech and academic customers remain a key risk, and execution on higher margin platforms is the main catalyst to watch.

Among recent announcements, the CE IVDR marking of the Ella benchtop immunoassay platform in the EU is particularly relevant. Like COMET and SPYRE, Ella extends Bio-Techne’s reach into higher value, workflow oriented applications, which analysts see as important for improving the company’s mix and supporting earnings growth even if core reagent demand remains constrained by tighter R&D budgets.

Yet against this innovation story, investors should be aware of how sustained weakness in biotech and academic funding could...

Read the full narrative on Bio-Techne (it's free!)

Bio-Techne's narrative projects $1.5 billion revenue and $250.1 million earnings by 2028. This requires 6.5% yearly revenue growth and an earnings increase of about $176.7 million from $73.4 million today.

Uncover how Bio-Techne's forecasts yield a $75.25 fair value, a 40% upside to its current price.

Exploring Other Perspectives

Some of the lowest ranked analysts take a more cautious view, assuming only about 6 percent annual revenue growth to roughly US$1.4 billion and earnings near US$292 million by 2029, highlighting how views on tariff risks and reliance on spatial biology can differ sharply and may need revisiting as new launches like SPYRE reshape expectations.

Explore 4 other fair value estimates on Bio-Techne - why the stock might be worth as much as 40% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bio-Techne research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Bio-Techne research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bio-Techne's overall financial health at a glance.

Interested In Other Possibilities?

Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

• Uncover the next big thing with 32 elite penny stocks that balance risk and reward.
• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com